References used in the tables

1 Thiagarajan P, Wu KK. In vitro assays for evaluating platelet function. In: Gresele P, Page CP, Fuster V, Vermylen J, editors. Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge: Cambridge University Press; 2002: 459–70.

2 Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989;113:1219-1224

3 Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991;77:2547-2552.

4 Finazzi G, Budde U, Michiels JJ. Bleeding time and platelet function in essential thrombocythaemia and other myeloproliferative disorders. Leuk Lymphoma 1996; 22 suppl. 1:71-78.

5 De Paepe A, Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome and other collagen vascular disorders. Br J Haematol 2004; 127: 491-500.

6 Rand ML, Leung R, Packham MA. Platelet Function Assays. Transfus.Apher.Sci 2003;28:301-317.

7 Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1–20.

8 Shenkman B, Savion N, Dardik R, Tamarin I, Varon D. Testing of platelet deposition on polystyrene surface under flow conditions by cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2001;99:353–61.

9 Varon D, Savion N. Cone and plate(let) analyzer. In: Michelson A, editor. Platelets. San Diego: Academic Press 2002: 337–45.

10 Varon D, Lashevski I, Brenner B, Beyar R, Lanir N, Tamarin I, et al. Cone and plate(let) analyzer: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998;135:187–93.

11 Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, Varon D, Savion N, Friedman SM, Feuerstein GZ. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion. J Pharmacol Exp Ther 2002;303:1114-20.

12 Cazenave JP, Packham MA, Mustard JF.Adherence of platelets to a collagen-coated surface: development of a quantitative method. J Lab Clin Med 1973 ;82:978-90.

13 Sun L, Feng S, Resendiz JC, Lu X, Durante W, Kroll MH.Role of the Pyk2-MAP kinase-cPLA2 signaling pathway in shear-dependent platelet aggregation. Ann Biomed Eng 2004 ;32:1193-201..

14 Resendiz JC, Feng S, Ji G, Kroll MH. von Willebrand factor binding to platelet glycoprotein Ib-IX-V stimulates the assembly of an alpha-actinin-based signaling complex. J Thromb Haemost 2004 ;2:161-9..

15 Resendiz JC, Feng S, Ji G, Francis KA, Berndt MC, Kroll MH.Purinergic P2Y12 receptor blockade inhibits shear- induced platelet phosphatidylinositol 3-kinase activation. Mol Pharmacol 2003 ;63:639-45.

16 Kroll MH, Feng S. Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal? Expert Rev Cardiovasc Ther 2005 ;3:941-51.

17 Varon D, Dardik R, Shenkman B, Kotev-Emeth S, Farzame N, Tamarin I, Savion N.A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997 ;85:283-94.

18 Kenet G, Lubetsky A, Shenkman B, Tamarin I, Dardik R, Rechavi G, Barzilai A, Martinowitz U, Savion N, Varon D. Cone and platelet analyzer (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol 1998 ;101:255-9.

19 Levy Y, Shenkman B, Tamarin I, Pauzner R, Shoenfeld Y, Langevitz P, Savion N, Varon D.Increased platelet deposition on extracellular matrix under flow conditions in patients with antiphospholipid syndrome who experience thrombotic events. Arthritis Rheum 2005 ;52:4011-7.

20 Knobler H, Savion N, Shenkman B, Kotev-Emeth S, Varon D. Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients. Thromb Res 1998 ;90:181-90.

21 Kroll MH, Feng S. Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal? Expert Rev Cardiovasc Ther 2005 ;3:941-51.

22 Spectre G, Brill A, Gural A, Shenkman B, Touretsky N, Mosseri E, Savion N, Varon D. A new point-of-care method for monitoring anti-platelet therapy: application of the cone and plate(let) analyzer. Platelets 2005 ;16:293-9.

23 Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004 ;109:3171-5.

24 Feng S, Lu X, Kroll MH. Filamin A binding stabilizes nascent glycoprotein Ibalpha trafficking and thereby enhances its surface expression. J Biol Chem 2005 ;280:6709-15.

25 Shenkman B, Savion N, Dardik R, Tamarin I, Varon D.Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2000 ;99:353-61.

26 Shenkman B, Schneiderman J, Tamarin I, Kotev-Emeth S, Savion N, Varon D Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods. Thromb Res 2001 ;102:311-7.

27. Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, Varon D, Savion N, Friedman SM, Feuerstein GZ.Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion. J Pharmacol Exp Ther 2002 ;303:1114-20.

28 Peerschke EI, Silver RT, Weksler B, Grigg SE, Savion N, Varon D. Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists. Br J Haematol 2004 ;127:195-203.

29 Chang HM and Robertson CR. Platelet aggregation by laminar shear and Brownian motion. Ann Biomed Eng 1976; 4: 151-83.

30 Frojmovic MM. Platelet aggregation in flow: Differential roles for adhesive receptors and ligands. Am Heart J Suppl 1998; 135: 5119-5131.

31 Xia Z, Frojmovic MM. Aggregation efficiency of activated normal or fixed platelets in a simple shear field: effect of shear and fibrinogen occupancy. Biophys J 1994; 66: 2110-201.

32 Frojmovic MM, Kasirer-Friede A, Goldsmith H. and Brown E. Surface-secreted von Willebrand Factor mediates aggregation of ADP-activated platelets at moderate shear stress: Facilitated by GPIb but controlled by GPIIb-IIIa. Thrombos Haemost 1997; 76: 568-576.

33 Bonnefoy A, Hantgan R, Legrand C, Frojmovic MM. A model of platelet aggregation involving multiple ineteractions of thrombospondin-1, fibrinogen and GPIIbIIIa receptor.J Bio. Chem 2001; 276: 5605-12.

34 Bonnefoy A, Liu Q, Jerome W Gray, Legrand C, and Frojmovic MM. Platelets in suspension require preactivation to adhere to immobilized fibrinogen. Annals New York Acad. Sci 2001; 936: 459-63.

35 Frojmovic MM, Nash G, and Diamond SL. Definitions in biorheology: cell aggregation and cell adhesion in flow. Recommendation of the Scientific Subcommittee on Biorheology of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2002;87:771.

36 Frojmovic M and Zolotarova E. Both shear and temperature can profoundly alter antithrombotic drug efficacy: demonstration with the P2Y12 ADP receptor antagonist, ARC-69931MX. J Thromb Haemost 2003 ; 1772.

37 Labarthe B, Frojmovic M and Legrand C. Inhibition and Reversal of Platelet Aggregation by αIIbβ3 Antagonists Depends on Flow Conditions:-Differential effects of Abciximab and Lamifiban. Br J Haematol 2005 ;131:348-55.

38 Falati S. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P- selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003; 197: 1585-98.

39 Ajzenberg N, Aubry P, Huisse M-G, Cachier A, ElAmara W, Feldman L, Himbert D, Baruch D, Guillin M-C, Steg G. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis. A case- control study. J American College Cardiology 2005; 45:1753.

40 Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001 ;98:3340-5.

41 Baumgartner HR, Haudenschild C. Adhesion of platelets to subendothelium. Ann NY Acad Sci 1972; 201: 22- 36.

42 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-79.

43 Baumgartner ER Effects of anticoagulation on the interaction of human platelets with subendothelium in flowing blood. Schweiz Med Wochenschr 1976; 106: 1367-8.

44 Sakariassen KS, Turitto VT, Baumgartner HR. Recollection on the development of flow devices for studying mechanisms of haemostasis and thrombosis in flowing whole blood. J Thromb Haemostas 2004; 2: 1681-90.

45 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to subendothelium. Nature 1979; 279: 636-8.

46 Sakariassen KS, Hanson SR, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb Res 2001; 104: 149-73.

47 Sakariassen KS, Turitto VT, Baumgartner HR. Recollection of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood. J Thromb Haemostas 2004; 2: 1681-90.

48 Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition and formation of mural thrombi. Microvasc Res 1973; 5: 167-79.

49 Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 1983; 102: 522-35.

50 Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: Distinction from and prerequisite for adhesion through integrins. Cell, 1991; 65: 859-873.

51 Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 1983; 102: 522-35.

52 Sakariassen KS, Joss R, Muggli R, Tschopp TB, Sage H, Baumgartner HR. Collagen type III induced ex vivo thrombogenesis in humans: role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis 1988; 19: 276- 84.

53 Sakariassen KS, Muggli R, Baumgartner HR. Measurements of platelet interaction with components of the vessel wall in flowing blood. In: Hawiger J, ed. Methods in Enzymology. New York Academic Press Inc 1989; 169: 33-70.

54 Sakariassen KS, Kuhn H, Muggli R, Baumgartner HR. Growth and stability of thrombi in flowing blood: assessment with of platelet surface interactions with computer-assisted morphometry. Thromb Haemostas 1988; 60: 392-8.

55 Barstad RM, Roald HE, Cui W, Turitto VT, Sakariassen KS. A perfusion chamber developed to investigate thrombus formation and shear profiles in flowing native blood at the apex of well-defined stenoses. Arterioscl Thromb 1994; 14: 1984-91.

56 Lerea KM, Cordero KP, Sakariassen KS, Kirk RI, Fried VA. Phosphorylation sites in the integrin β3 cytoplasmic domain in intact platelets. J Biol Chem 1999; 274: 1914-19.

57 Diquelou A, Dupouy D, Cariou R, Sakariassen KS, Boneu B, Cadroy Y. A comparative study of the anticoagulant and antithrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis. Thromb Haemostas 1995; 74: 1286-92.

58 Orvim U, Barstad RM, Stormorken H, Brosstad F, Sakariassen KS. Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood. Br J Haematol 1996; 95: 389-98.

59 Bossavy JP, Sakariassen KS, Barret A, Boneu B, Cadroy Y. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemostas 1998; 79: 162-8.

60 Holme PA, Orvim U, Hamers MJAG, Solum NO, Brosstad FR, Barstad RM, Sakariassen KS. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with severe stenoses. Art Thromb Vasc Biol 1997; 17: 646-53.

61 Sakariassen KS, Cattaneo M, van der Berg A, Ruggeri ZM, Mannucci PM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 1984; 64: 1408-15.

62 Fressinaud E, Sakariassen KS, Rothschild C, Baumgartner HR, Meyer D. Shear-rate dependent impairment of thrombus growth on collagen in nonanticoagulated blood from patients with von Willebrand disease and Hemophilia A. Blood 1992; 80: 988-94.

63 Tschopp TB, Weiss HJ, Baumgartner HR. Decreased platelet adhesion of platelets to subendothelium in von Willebrand’s disease. J Lab Clin Med 1974; 83: 296-300.

64 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate dependent decrease of adhesion in von Willebrand’s disease and the Bernard- Soulier syndrome. J Lab Clin Med 1978; 92: 750-64.

65 Sakariassen KS, Nievelstein PFEM, Coller B, Sixma JJ. The role of platelet membrane glycoprotein Ib and IIb/IIIa in platelet adherence to artery subendothelium. Br J Haematol 1986; 63: 681-91.

66 Weiss HJ, Turitto VT, Baumgartner HR. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules. Blood 1986; 67: 322-30.

67 Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephritic syndrome under flow conditions. J Clin Invest 1994; 93: 204-11.

68 Barstad RM, Hamers MJAG, Kierulf P, Westvik A-B, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/factor VIIa-dependent platelet thrombus formation when exposed to flowing nonanticoagulated human blood. Art Thromb Vasc Biol 1995; 15: 11-6.

69 Roald HE, Barstad RM, Bakken IJ, Roald B, Lyberg T, Sakariassen KS. Initial interactions of platelets and plasma proteins in flowing non-anticoagulated human blood with the artificial surfaces Dacron and PTFE. Blood Coag Fibrinol 1994; 5: 355-63.

70 Fredrickson BJ, Turner NA, Kleiman NS, Graziadei N, Maresh K, Mascelli MA, Effron MB, McIntire LV. Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty. Circulation 2000; 101:1122-9.

71 Sakariassen KS, Orning L, Stormorken H. Role of ADP and thromboxanes in human thrombus formation in ex vivo models Taylor & Francis Health Sciences, part of the Taylor & Francis Group 1997; 8: 85 – 390.

72 Remijn JA, Wu YP, Jeninga EH, IJsseldijk MJ, van Willigen G, de Groot PG,Sixma JJ, Nurden AT, Nurden P. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002;22:686-91.

73 Lepantalo A, Beer JH, Siljander P, Syrjala M, Lassila R.Variability in platelet responses to collagen--comparison between whole blood perfusions, traditional platelet function tests and PFA-100. Thromb Res 2001;103:123-33.

74 Ozalski M, Boncler M, Golanski J, Watala C. Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation. Biochem Pharmacol 2001;62:1399-408.

75 Orvim U, Barstad RM, Stormorken H, Brosstad F, Sakariassen KS. Immunologic quantification of fibrin deposition in thrombi formed in flowing native human blood. Br J Haematol 1996; 95: 389-98.

76 Bossavy JP, Sakariassen KS, Barret A, Boneu B, Cadroy Y. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemostas 1998; 79: 162-8.

77 Nesbitt WS, Kulkarni S, Giuliano S, Goncalves I, Dopheide SM, Yap CL, Harper IS, Salem HH, Jackson SP. Distinct glycoprotein Ib/V/IX and integrin aIIbb3-dependent calcium signals cooperatively regulate platelet adhesion under flow. J Biol Chem 2002;277:2965-2972.

78 Yuan YP, Kulkarni S, Ulsemer P, Cranmer SL, Yap CL, Nesbitt WS, Harper I, Mistry N, Dopheide SM, Hughan SC, Williamson D, de la Salle C, Salem HH, Lanza F, Jackson SP. The von Willebrand factor-glycoprotein Ib/V/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib/V/IX-transfected cells. J Biol Chem 1999;274:36241-36251.

79 Cosemans JMEM, Kuijpers MJE, Lecut C, Loubele STBG, Heeneman S, Jandrot-Perrus M, Heemskerk JWM. Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions. Atherosclerosis 2005;181: 19-27.

80 Siljander PRM, Munnix ICA, Smethurst PA, Deckmyn H, Lindhout T, Ouwehand WH, Farndale RW, Heemskerk JWM. Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood. Blood 2004;103:1333-1341.

81 Lecut C, Schoolmeester A, Kuijpers MJE, Broers JLV, van Zandvoort MAMJ, Vanhoorelbeke K, Deckmyn H, Jandrot-Perrus M,Heemskerk JWM. Principal role of glycoprotein VI in 2 1 and IIb 3 activation during collagen-induced thrombus formation. Arterioscler. Thromb Vasc Biol 2004;24:1727-1733.

82 Kuijpers MJE, Schulte V, Bergmeier W, Lindhout T, Brakebusch C, Offermanns S, Fässler R, Heemskerk JWM, Nieswandt B. Complementary roles of glycoprotein VI and 2 1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. FASEB J 2003;17:685-687.

83 Auger JM, Kuijpers MJE, Senis YA, Watson SP, Heemskerk JWM. Adhesion of human and mouse platelets to collagen under shear: a unifying model. FASEB J 2005;10:1096-.

84 Kuijpers MJE, Nieuwenhuys CMA, Feijge MAH, Kloots W, Giesen PLA, Jerling JC, oude Egbrink MGA, Heemskerk JWM. Regulation of tissue factor-induced coagulation and platelet aggregation in flowing whole blood. Thromb Haemost 2005;93:97-105.

85 Rand ML, Leung R, Packham MA. Platelet Function Assays. Transfus Apher Sci 2003;28:301-317.

86 Keuren JFW, Ulrichts H, Feijge MAH, Hamulyak K, Deckmyn H, Lindhout T,Heemskerk JWM. Integrin aIIbb3 and shear-dependent action of glycoprotein Iba stimulate platelet-dependent thrombin formation in stirred plasma. J Lab Clin Med 2003;141:350-358.

87 Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001 ;103:1488-91.

88 Moritani Y, Sato K, Shigenaga T, Hisamichi N, Ichihara M, Akamatsu S, Suzuki K, Nii T, Kaku S, Kawasaki T, Matsumoto Y, Inagaki O, Tomioka K, Yanagisawa I. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist. Eur J Pharmacol 2002 ;439:43-52.

89 Haga JH, Slack SM, Jennings LK. Comparison of shear stress-induced platelet microparticle formation and phosphatidylserine expression in presence of alphaIIbbeta3 antagonists. J Cardiovasc Pharmacol 2003; 41:363- 71.

90 Kitai T, Nishikawa M, Tanigawa T, Okinaka T, Wada H, Shiku H, Ikeda Y, Ito M, Isaka N, Nakano T. Inhibition by combined therapy with ticlopidine and aspirin of enhanced platelet aggregation during physical exercise in patients with coronary artery disease. Am Heart J 2001 ;142:E1.

91 White MM, Jennings LK. Platelet Protocols. Research and Clinical Laboratory Procedures. San Diego: Academic Press; 1999.

92 Packham MA, Bryant NL, Guccione MA, Kinlough-Rathbone RL, Mustard JF. Effect of the concentration of Ca2þ in the suspending medium on the responses of human and rabbit platelets to aggregating agents. Thromb Haemost 1989;62:968–76.

93 Nurden AT. Inherited abnormalities of platelets. Thromb Haemost 1999;82:468–80.

94 Veyradier A, Fressinaud E, Meyer D. Laboratory diagnosis of von Willebrand disease. Int J Clin Lab Res 1998;28:201–10.

95 Frelinger AL 3rd, Hillman RSNovel methods for assessing platelet function. Am Heart J 1998 ;135:S184-6

96 Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK, The Platelet physiology Subcommittee of the SSC of the ISTH. Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006;4:312-9.

97 Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.Am Heart J 2004;147:E17.

98 Madan M, Berkowitz SD, Christie DJ, Jennings LK, Smit AC, Sigmon KN, Glazer S, Tcheng JE. Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. Am Heart J. 2001;141:226-33.

99 Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer PFA-100TM. Semin Thromb Hemost 1995; 21(Suppl 2):106–12.

100 Rand ML, Carcao MD, Blanchette VS. Use of the PFA-100_in the assessment of primary, platelet-related hemostasis in a pediatric setting. Semin Thromb Hemost 1998;24:523–9.

101 Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152–63.

102 Francis JL. Platelet Function Analyzer (PFA)-100. In: Michelson A, editor. Platelets. San Diego: Academic Press 2002: 325–35.

103 Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in-vitro platelet function analyzer, PFA-100TM. Clin Appl Thromb Hemost 1996;2: 241–9.

104 Heilmann EJ, Kundu SK, Sio R, Garcia C, Gomez R, Christie DJ. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 1997;87:159–64.

105 Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost 1999;5:122–30.

106 Dean JA, Blanchette VS, Carcao MD, Stain AM, Sparling CR, Siekmann J, et al. von Willebrand disease in a pediatric-based population––comparison of type 1 diagnostic criteria and use of the PFA-100_ and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000;84:401–9.

107 Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, et al. Screening for von illebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325–31.

108 Cattaneo M, Federici AB, Lecchi A, Agati B, Lombardi R, Stabile F, et al. Evaluation of the PFA-100_ system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999;82:35– 9.

109 Hezard N, Metz D, Nazeyrollas P, Droulle C, Elaerts J, Potron G, et al. Use of the PFA-100TM apparatus to assess platelet function in patients undergoing PTCA during and after infusion of cE3 Fab in the presence of other antiplatelet agents. Thromb Haemost 2000;83:540–4.

110 Borzini P, Lazzaro A, Mazzucco L. Evaluation of the hemostatic function of stored platelet concentrates using the platelet function analyzer (PFA-100). Haematologica 1999;84:1104–9.

111 Carcao MD, Blanchette VS, Wakefield CD, Clark DS, He L, Rand ML. Use of the platelet function analyzer, PFA- 100, in assessing effectiveness of platelet transfusions. Thromb Haemost 2001;(Suppl):1224.

112 Carcao MD, Blanchette VS, Stephens D, He L, Wakefield CW, Butchart S, et al. Assessment of thrombocytopenic disorders using the platelet function analyzer (PFA-100_). Br J Haematol 2002;117:961–4.

113 Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hollman RS, et al. Rapid platelet-function assay. An automated and quantitative cartridge-base method. Circulation 1999;99:620–5.

114 Barstad RM, Orvim U, Hamers MJAG, Tjonnfjord G, Brosstad FR, Sakariassen KS. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb Haemostas 1996; 75: 827-32.

115 Weiss HJ, Turitto VT, Baumgartner HR. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules. Blood 1986; 67: 322-30.

116 Weiss HJ, Turitto VT, Baumgartner HR. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelet defects. J Clin Invest 1986; 78: 1072-82.

117 Barstad RM, Hamers MJAG, Stephens RW, Sakariassen KS. Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa dependent thrombus formation. Blood 1995; 86: 212-8.

118 Nieuwenhuis HK, Sakariassen KS, Houdijk WPM, Nievelstein PFEM, Sixma JJ. Deficiency of platelet membrane glycoprotein Ia is associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986; 68: 692-5.

119 Cadroy Y, Sakariassen KS, Charlet JP, Thalamas C, Boneu P, Sie P. Role of 4 platelet membrane glycoprotein polymorphisms on experimental arterial thrombus formation in men. Blood 2001; 98: 3159-61.

120 Cadroy Y, Sakariassen KS, Grandjean H, Thalamas C, Boneu B, Sie P. The effect of platelet PlA polymorphism on experimental thrombus formation in man depends on blood flow and thrombogenic surface. Thromb Haemostas 2001; 85: 1097-103.

121 Diaz-Ricart M, Tandon NN, Carretero M, Ordinas A, Bastida E, Jamieson GA. Platelets lacking functional CD36 (glycoprotein IV) show reduced adhesion to collagen in flowing whole blood. Blood 1993; 82: 491-6.

122 Joutsi-Korhonen L, Smethurst PA, Rankin A, Gray E, Ijsseldijk M, Onley CM, Watkins NA, Williamson LM, Goodall AH, de Groot PG, Farndale RW, Ouwehand WH. The low-frequency allele of the platelet collagen signalling receptor glycoprotein VI is associated with reduced functional responses and expression. Blood 2003; 101: 4372-9.

123 Stormorken H, Holmsen H, Sund R, Sakariassen KS, Hovig T, Jellum E, Solum N-O. Studies on the haemostatic defect in a complicated syndrome – an inverse Scott syndrome platelet membrane abnormality. Thromb Haemostas 1995; 74: 1244-51.

124 Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephritic syndrome under flow conditions. J Clin Invest 1994; 93: 204-11.

125 Zwaginga JJ, IJsseldijk MJ, de Groot PG, Kooistra M, Vos J, van Es A, Koomans HA, Struyvenberg A, Sixma JJ. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb Haemostas 1991; 66: 638-47.

126 Zwaginga JJ, IJsseldijk MJ, de Groot PG, de Bos-Kuil RL, Sixma JJ. Defects in platelet adhesion and aggregate formation in uremic bleeding disorders can be attributed to factors in plasma. Art Thromb 1991; 11: 733-44.

127 Barstad RM, Stormorken H, Orning L, Stephens RW, Petersen LB, Kierulf P, Sakariassen KS. Reduced thrombus formation in native blood of homozygous factor VII deficient patients at high arterial wall shear rate. Blood 1994; 84: 3371-7.

128 Weiss HJ, Turitto VT, Vicic WJ, Baumgartner HR. Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI tham in factor VIII and IX deficiency. Blood 1984; 63: 1004-14.

129 Remijn JA, Wu YP, IJsseldijk MJ, Zwaginga JJ, Sixma JJ, de Groot PG. Absence of fibrinogen in afibrinogenimia results in large but loosely packed thrombi under flow conditions. Thromb.Haemostas 2001; 85: 736-742.

130 Weiss HJ, Hawiger J, Ruggeri ZM, Turitto VT, Thiagarajan P, Hoffmann T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest 1989; 83: 288-97.

131 Cadroy Y, Lemozy S, Diquelou A, Ferrieres J, Douste-Blazy P, Boneu B, Sakariassen KS. Human type II hyperlipoproteinemia enhances platelet-collagen adhesion in flowing non-anticoagulated blood. Art Thromb 1993; 13: 1650-4.

132 Nievelstein PF, Sixma JJ, Ottenhof-Rovers M, Wynne HJ, de Groot PG, Banga JD. Platelet adhesion and aggregate formation in type 1 diabetes under flow conditions. Diabetes 1991; 40: 1410-7.

133 Ferreira IA, Mocking AIM, Feijge MAH, Gorter G, van Haeften TW, Heemskerk JWM, Akkerman JWN. Platelet inhibition by insulin is absent in type 2 diabetes. Art.Thromb.Vasc. Biol 2006; 26: 417-422

134 Cadroy Y, Diquelou A, Dupouy D, Bossavy JP, Sakariassen KS, Sie P, Boneu B. The thrombomodulin / protein C / protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium. Art Thromb Vasc Biol 1997; 17: 520-7.

135 Weiss HJ, Turitto VT, Vicic WJ, Baumgartner HR. Effect of aspirin and dipyridamole on the interaction of human platelets with subendothelium: studies using citrated and native blood. Thromb Haemostas 1981; 45: 136-41.

136 Roald HE, Orvim U, Bakken IJ, Barstad RM, Kierulf P, Sakariassen KS. Modulation of thrombotic responses in moderately stenosed arteries by cigarette smoking and aspirin ingestion. Art Thromb 1994; 14: 617-21.

137 Bossavy JP, Thalamas C, Sagnard L, Barret A, Sakariassen KS, Boneu B, Cadroy Y. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood 1998; 92: 1518-25.

138 Roald HE, Barstad RM, Kierulf P, Skjorten P, Dickinson JP, Kieffer G, Sakariassen KS, Clopidogrel – a platelet inhibitor which inhibits thrombogenesis in human non-anticoagulated blood independently of the blood flow conditions. Thromb Haemostas 1994; 71: 665-72.

139 Roald HE, Barstad RM, Engen A, Kierulf P, Skjorten F, Sakariassen KS. HN-11500 – a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb Haemostas 1994; 71: 103-9.

140 Weiss HJ, Turitto VT, Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood 1979; 53: 244-50.

141 Fressinaud E, Girma JP, Sadler JF, Baumgartner HR, Meyer D. Synthetic RGDS-containing peptides of von Willebrand factor inhibit platelet adhesion to collagen. Thromb Haemostas 1990; 64: 589-93.

142 Aznar-Salatti J, Anton P, Nemerson Y, Sakariassen KS. Modulation of procoagulant activity of extracellular endothelial matrix by anti-tissue factor antibody and the synthetic peptide arg-gly-asp-val. Experiments with flowing non-anticoagulated blood. Blood Coag Fibrinol 1993; 4: 881-90.

143 Kirchhofer D, Tschopp TB, Steiner B, Baumgartner HR. Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Blood 1995; 86: 3815-22.

144 Sakariassen KS, Fressinaud E, Girma J-P, Meyer D, Baumgartner HR. Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen. Ann NY Acad Sci 1987; 516: 52-65. . 145 Bossavy JP, Sakariassen KS, Thalamas C, Boneu B, Cadroy Y. Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis. Effect of anticoagulation level and combination therapy with aspirin. Art Thromb Vasc Biol 1999; 19: 2269-75.

146 Barstad RM, Arnesen H, Sakariassen KS. Unpublished observation

147 Inauen W, Bombeli T, Baumgartner HR, Haeberli A, Straub PW. Effects of the oral anticoagulant phenprocoumon on blood coagulation and thrombogenesis induced by rabbit aorta subendothelium exposed to flowing human blood: role of dose and shear rate. J Lab Clin Med 1991; 118: 280-8.

148 Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR. Endothelial cells stimulated with tumor necrosis factor- alpha express varying amounts of tissue factor resulting in inhomogeneous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest 1994; 93: 2073-83.

149 Inauen W, Baumgartner HR, Bombeli T, Haeberli A, Straub PW. Dose- and shear rate-dependent effects of heparin on thrombogenesis induced by rabbit aorta subendothelium exposed to flowing blood. Arteriosclerosis 1990; 10: 607-15.

150 Barstad RM, Stephens RW, Hamers MJ, Sakariassen KS. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb Haemostas 2000; 83: 334-7.

151 Bossavy JP, Sakariassen KS, Rubsamen K, Thalamas C, Boneu B, Cadroy Y. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis. Art Thromb Vasc Biol 1999; 19: 1348-53.

152 Cadroy Y, Bossavy JP, Thalamas C, Sagnard L, Sakariassen KS, Boneu B. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101: 2823-8.

153 Bossavy JP, Sakariassen KS, Thalamas C, Boneu B, Cadroy Y. Antithrombotic efficacy of the vitamin K antagonist fluindione in a human ex vivo model of arterial thrombosis. Effect of anticoagulation level and combination therapy with aspirin. Art Thromb Vasc Biol 1999; 19: 2269-75.

154 Cadroy Y, Thalamas C, Sakariassen KS, Boneu B. Superior efficacy of clopidogrel plus acetylsalicyclic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombosis in healthy volunteers. Thromb Res 2005; 116: 293-300.

155 Barstad RM, Hamers MJAG, Kierulf P, Westvik A-B, Sakariassen KS. Procoagulant human monocytes mediate tissue factor/factor VIIa-dependent platelet thrombus formation when exposed to flowing nonanticoagulated human blood. Art Thromb Vasc Biol 1995; 15: 11-6.

156 Orvim U, Barstad RM, Orning L, Petersen LB, Ezban M, Hedner U, Sakariassen KS. Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood. Art Thromb Vasc Biol 1997; 17: 3049-56.

157 Kirchhofer D, Tschopp TB, Baumgartner HR. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Art Thromb Vasc Biol 1995; 15: 1098-106.

158 Lindahl AK, Sandset PM, Thune-Wiiger M, Nordfang O, Sakariassen KS. Tissue factor pathway inhibitor prevents fibrin deposition on procoagulant subendothelial matrix when exposed to flowing non-anticoagulated human blood. Blood Coag Fibrinol 1994; 5: 755-60.

159 Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired aIIbB3 deficiency to endotheilial cell matrix and collagen under conditions of flow via tissue factor-dependent thrombin generation. Blood 2003; 101:1864-70

160 Weiss HJ, Baumgartner HR, Tschopp TB, Turitto VT, Cohen D. Correction by Factor VIII of the impaired platelet adherence to subendothelium in von Willebrand’s disease. Blood 1978; 51: 267-79.

161 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-von Willebrand factor bound to subendothelium. Nature 1979; 279: 636-8.

162 Sixma JJ, Sakariassen KS, Beeser-Visser NH, Ottenhof-Rovers M, Bolhuis PA. Adhesion of platelets to human artery subendothelium: effect of factor VIII-von Willebrand factor of various multimeric composition. Blood 1984; 63: 128-39.

163 Sakariassen KS, Bolhuis PA, Blomback M, Thorell L, Blomback B, Sixma JJ. Association between bleeding time and platelet adherence to artery subendothelium. Thromb Haemostas 1984; 52: 144-7.

164 Aznar-Salatti J, Escolar G, Arnau M, Carretero M, White JG, Garcia-Barbal J, Castillo R, Ordinas A. An intermediate-purity factor VIII concentrate supports platelet adhesion underflow conditions. Haemophilia 1997; 3: 14-20.

165 Orvim U, Barstad RM, Vlasuk GP, Sakariassen KS. Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear dependent thrombus formation. Art Thromb Vasc Biol 1995; 15: 2188-94.

166 Barstad RM, Roald HE, Petersen LB, Stokke KT, Kierulf P, Sakariassen KS. Dietary supplement of omega-3 fatty acids has no effect on acute collagen-induced thrombus formation in flowing native blood. Blood Coag Fibrinol 1995; 6: 374-81.

167 Inauen W, Stocker G, Haeberli A, Straub PW. Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood. Contraception 1991; 43: 435-46.

168 Sakariassen KS, Barstad RM, Hamers MJAG, Stormorken H. Iohexol, platelet activation and thrombosis. I. Iohexol-induced platelet secretion does not affect thrombus formation in native blood. Acta Radiol 1998; 39: 349- 54.

169 Sakariassen KS, Buchmann M, Hamers MJAG, Stormorken H. Iohexol, platelet activation and thrombosis. II. Iohexol-induced platelet secretion does not affect collagen- or tissue factor-induced thrombus formation in blood anticoagulated with heparin and aspirin. Acta Radiol 1998; 39: 355-61.

170 van Heerde WL, Sakariassen KS, Hemker HC, Sixma JJ, Reutelingsberger CCPM, de Groot PG. Annexin V inhibits the procoagulant activity of TNF-stimulated endothelial cells under flow conditions. Art Thromb 1994; 14: 824-30.